Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Squalamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 2/20 | 0.97 |
| ▸ | NR1H4 | Q96RI1 | 8/20 | 0.53 |
| ▸ | SLC10A1 | Q14973 | 3/20 | 0.51 |
| ▸ | GPBAR1 | Q8TDU6 | 9/20 | 0.51 |
| ▸ | SLC10A2 | Q12908 | 2/20 | 0.48 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.48 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.48 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.48 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Squalamine SCHEMBL14441307 | 1.00 | PTPN1 (0.97) | PTPN1NR1H4SLC10A1GPBAR1SLC10A2 | |
| Squalamine SCHEMBL17359656 | 1.00 | PTPN1 (0.97) | PTPN1NR1H4SLC10A1GPBAR1SLC10A2 | |
| Squalamine SCHEMBL16072074 | 1.00 | PTPN1 (0.97) | PTPN1NR1H4SLC10A1GPBAR1SLC10A2 | |
| Squalamine SCHEMBL14430016 | 1.00 | PTPN1 (0.97) | PTPN1NR1H4SLC10A1GPBAR1SLC10A2 | |
| Squalamine SCHEMBL12836 | 1.00 | PTPN1 (0.97) | PTPN1NR1H4SLC10A1GPBAR1SLC10A2 | |
| Squalamine SCHEMBL18838926 | 1.00 | PTPN1 (0.97) | PTPN1NR1H4SLC10A1GPBAR1SLC10A2 | |
| Squalamine SCHEMBL22356672 | 1.00 | PTPN1 (0.97) | PTPN1NR1H4SLC10A1GPBAR1SLC10A2 | |
| Squalamine SCHEMBL21248627 | 1.00 | PTPN1 (0.97) | PTPN1NR1H4SLC10A1GPBAR1SLC10A2 | |
| Squalamine SCHEMBL20850040 | 1.00 | PTPN1 (0.97) | PTPN1NR1H4SLC10A1GPBAR1SLC10A2 | |
| Squalamine SCHEMBL13014098 | 1.00 | PTPN1 (0.97) | PTPN1NR1H4SLC10A1GPBAR1SLC10A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234983-A1 | SQUALAMINE CRYSTALLINE POLYMORPHS | ENTERIN, INC. (US) | 2023-07-27 | — | — | US | disclosed |
| US-20230159582-A1 | CRYSTALLINE FORMS OF SQUALAMINE | ENTERIN, INC. (US) | 2023-05-25 | — | — | US | disclosed |
| US-20230125585-A1 | DOSING PROTOCOLS AND REGIMENS FOR AMINOSTEROL TREATMENT | ENTERIN, INC. (US) | 2023-04-27 | — | — | US | disclosed |
| US-20180042942-A1 | Compounds that are Analogs of Squalamine, Used as Antibacterial Agents | VIRBAC (FR) | 2018-02-15 | — | — | US | disclosed |
| US-20160362444-A1 | Method for Treating Diabetes | OHR PHARMACEUTICAL INC. (US) | 2016-12-15 | — | — | US | disclosed |
| US-20160362444-A1 | Method for Treating Diabetes | OHR PHARMACEUTICAL INC. (US) | 2016-12-15 | — | — | US | disclosed |
| US-20140249122-A1 | ANTI-DIABETIC AMINOSTEROID DERIVATIVES | UNIVERSITE NICE SOPHIA ANTIPOLIS (FR) | 2014-09-04 | — | — | US | disclosed |
| US-20140249122-A1 | ANTI-DIABETIC AMINOSTEROID DERIVATIVES | UNIVERSITE NICE SOPHIA ANTIPOLIS (FR) | 2014-09-04 | — | — | US | disclosed |
| US-7728157-B2 | Regioselective and stereoselective oxidation of fused ring systems useful for the preparation of aminosterols | OHR PHARMACEUTICAL INC. (US) | 2010-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160362444-A1 | Method for Treating Diabetes | PPP3CB, PPP4C, PNLIP | PTPN1 133/4885NR1H4 342/4885SLC10A1 536/4885 |
| US-20180042942-A1 | Compounds that are Analogs of Squalamine, Used as Antibacterial Agents | SQLE, MTX1, SPIN1 | PTPN1 3218/4885NR1H4 800/4885SLC10A1 124/4885 |
| US-20140249122-A1 | ANTI-DIABETIC AMINOSTEROID DERIVATIVES | GPR119, ADIPOR2, ADIPOR1 | PTPN1 1925/4885NR1H4 15/4885SLC10A1 446/4885 |
| US-20230159582-A1 | CRYSTALLINE FORMS OF SQUALAMINE | HLA-DRB1, SQLE, SFPQ | PTPN1 834/4885NR1H4 539/4885SLC10A1 38/4885 |
| US-20230234983-A1 | SQUALAMINE CRYSTALLINE POLYMORPHS | HLA-DRB1, SLC10A2, HLA-A | PTPN1 812/4885NR1H4 305/4885SLC10A1 23/4885 |
| US-20230125585-A1 | DOSING PROTOCOLS AND REGIMENS FOR AMINOSTEROL TREATMENT | HSD3B1, HSD17B7, HSD11B1 | PTPN1 2492/4885NR1H4 75/4885SLC10A1 94/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.